LGND insider transaction filings
LIGAND PHARMACEUTICALS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen LGND transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Haas Jason — Director | Option exercise (M): 6,138 @ $51.56 · Sale (S): 7,138 @ $292.81 · Option exercise (M): 6,138 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Espinoza Octavio — Chief Financial Officer | Option exercise (M): 16,179 @ $52.84 · Option exercise (M): 2,074 @ $70.04 · Option exercise (M): 2,869 @ $55.75 · Option exercise (M): 7,171 @ $57.22 · Option exercise (M): 3,348 @ $68.74 · Sale (S): 31,641 @ $292.06 · +5 more | EDGAR |
| 2026-08-04 | 4 | Reardon Andrew — CLO & Secretary | Option exercise (M): 5,000 @ $52.27 · Sale (S): 105 @ $284.14 · Sale (S): 33 @ $284.55 · Sale (S): 157 @ $285.74 · Sale (S): 1,032 @ $286.80 · Sale (S): 1,214 @ $287.77 · +6 more | EDGAR |
| 2026-07-06 | 4 | Reardon Andrew — CLO & Secretary | Other (J): 132 @ $160.71 · Option exercise (M): 5,000 @ $52.27 · Sale (S): 396 @ $308.99 · Sale (S): 104 @ $310.20 · Sale (S): 1,119 @ $311.72 · Sale (S): 1,081 @ $312.28 · +5 more | EDGAR |
| 2026-07-06 | 4 | Espinoza Octavio — Chief Financial Officer | Other (J): 17 @ $160.71 | EDGAR |
| 2026-07-06 | 4 | Davis Todd C — Chief Executive Officer, Director | Other (J): 132 @ $160.71 | EDGAR |
| 2026-06-18 | 4 | Sabba Stephen L — Director | Option exercise (M): 2,145 @ $66.13 · Sale (S): 2,145 @ $254 · Option exercise (M): 2,145 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Haas Jason — Director | Option exercise (M): 3,000 @ $51.56 · Option exercise (M): 1,000 @ $51.56 · Sale (S): 3,000 @ $255.01 · Sale (S): 3,461 @ $256.08 · Option exercise (M): 3,000 (derivative) @ $0 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Aryeh Jason — Director | Grant/award (A): 836 @ $0 · Sale (S): 500 @ $250 · Sale (S): 4,500 @ $250 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | LAMATTINA JOHN L — Director | Sale (S): 257 @ $247.22 · Sale (S): 232 @ $248.11 · Sale (S): 697 @ $249.53 · Sale (S): 3,405 @ $251.62 | EDGAR |
| 2026-06-09 | 4 | Zimmermann Martine — Director | Grant/award (A): 836 @ $0 · Tax withholding (F): 182 @ $237 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Haas Jason — Director | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Gray Nancy Ryan — Director | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Sabba Stephen L — Director | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | KOZARICH JOHN W — Director | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | LAMATTINA JOHN L — Director | Grant/award (A): 836 @ $0 · Grant/award (A): 2,938 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Reardon Andrew — CLO & Secretary | Option exercise (M): 5,000 @ $52.27 · Sale (S): 491 @ $223.95 · Sale (S): 677 @ $225.20 · Sale (S): 1,432 @ $225.97 · Sale (S): 400 @ $226.78 · Sale (S): 584 @ $228.57 · +3 more | EDGAR |
| 2026-05-28 | 4 | Espinoza Octavio — Chief Financial Officer | Option exercise (M): 764 @ $63.62 · Option exercise (M): 972 @ $52.84 · Option exercise (M): 972 (derivative) @ $0 · Option exercise (M): 764 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | KOZARICH JOHN W — Director | Sale (S): 80 @ $227.37 · Sale (S): 1 @ $229.87 · Sale (S): 165 @ $231.87 · Sale (S): 105 @ $232.57 · Sale (S): 116 @ $234.09 · Option exercise (M): 459 @ $69.51 · +5 more | EDGAR |
| 2026-05-04 | 4 | Reardon Andrew — CLO & Secretary | Option exercise (M): 5,000 @ $52.27 · Sale (S): 600 @ $227.45 · Sale (S): 932 @ $228.75 · Sale (S): 98 @ $229.71 · Sale (S): 370 @ $230.87 · Sale (S): 780 @ $232.04 · +3 more | EDGAR |
| 2026-04-02 | 4 | Reardon Andrew — CLO & Secretary | Option exercise (M): 5,000 @ $52.27 · Sale (S): 460 @ $198.85 · Sale (S): 1,302 @ $199.72 · Sale (S): 1,238 @ $200.94 · Sale (S): 700 @ $201.90 · Sale (S): 963 @ $203.22 · +2 more | EDGAR |
| 2026-04-02 | 4 | KOZARICH JOHN W — Director | Sale (S): 146 @ $199.97 · Sale (S): 40 @ $201.24 · Sale (S): 79 @ $202.42 · Sale (S): 43 @ $202.91 · Sale (S): 159 @ $204.26 | EDGAR |
| 2026-03-31 | 4 | LAMATTINA JOHN L — Director | Option exercise (M): 2,161 @ $114.15 · Sale (S): 2,161 @ $200.76 · Option exercise (M): 2,161 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Reardon Andrew — CLO & Secretary | Grant/award (A): 4,513 @ $0 · Grant/award (A): 21,525 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Espinoza Octavio — Chief Financial Officer | Grant/award (A): 4,933 @ $0 · Grant/award (A): 23,527 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Davis Todd C — Chief Executive Officer, Director | Grant/award (A): 10,495 @ $0 · Grant/award (A): 50,058 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Sabba Stephen L — Director | Sale (S): 1,000 @ $207.87 | EDGAR |
| 2026-03-13 | 4 | Espinoza Octavio — Chief Financial Officer | Option exercise (M): 2,405 @ $92.65 · Sale (S): 3,057 @ $225 · Option exercise (M): 2,405 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Reardon Andrew — CLO & Secretary | Option exercise (M): 5,000 @ $52.27 · Sale (S): 100 @ $197.70 · Sale (S): 100 @ $199.00 · Sale (S): 207 @ $199.96 · Sale (S): 93 @ $200.62 · Sale (S): 300 @ $201.70 · +7 more | EDGAR |
| 2026-03-06 | 4 | Espinoza Octavio — Chief Financial Officer | Option exercise (M): 1,607 @ $58.49 · Option exercise (M): 466 @ $80.72 · Sale (S): 699 @ $198.71 · Sale (S): 53 @ $200.08 · Sale (S): 698 @ $201.09 · Sale (S): 950 @ $201.73 · +9 more | EDGAR |
| 2026-03-05 | 4 | Sabba Stephen L — Director | Option exercise (M): 2,034 @ $69.51 · Sale (S): 2,034 @ $201.50 · Option exercise (M): 2,034 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | KOZARICH JOHN W — Director | Sale (S): 47 @ $197.14 · Sale (S): 204 @ $199.69 · Sale (S): 41 @ $200.40 · Sale (S): 83 @ $201.65 · Sale (S): 50 @ $202.54 · Sale (S): 42 @ $203.57 | EDGAR |
| 2026-02-18 | 4 | Reardon Andrew — CLO & Secretary | Grant/award (A): 6,928 @ $0 · Tax withholding (F): 3,211 @ $183.83 · Grant/award (A): 8,810 @ $0 · Tax withholding (F): 4,083 @ $183.83 · Tax withholding (F): 593 @ $183.83 · Tax withholding (F): 801 @ $183.83 · +1 more | EDGAR |
| 2026-02-18 | 4 | Espinoza Octavio — Chief Financial Officer | Grant/award (A): 7,390 @ $0 · Tax withholding (F): 3,761 @ $183.83 · Grant/award (A): 8,810 @ $0 · Tax withholding (F): 4,483 @ $183.83 · Tax withholding (F): 1,026 @ $183.83 · Tax withholding (F): 1,223 @ $183.83 · +1 more | EDGAR |
| 2026-02-18 | 4 | Davis Todd C — Chief Executive Officer, Director | Grant/award (A): 20,782 @ $0 · Tax withholding (F): 8,178 @ $183.83 · Grant/award (A): 39,644 @ $0 · Tax withholding (F): 15,600 @ $183.83 · Tax withholding (F): 2,039 @ $183.83 · Tax withholding (F): 4,255 @ $183.83 · +1 more | EDGAR |
| 2026-02-04 | 4 | KOZARICH JOHN W — Director | Sale (S): 39 @ $191 · Sale (S): 1 @ $192.18 · Sale (S): 23 @ $195.60 · Sale (S): 381 @ $196.36 · Sale (S): 23 @ $197.19 | EDGAR |
| 2026-01-06 | 4 | Espinoza Octavio — Chief Financial Officer | Other (J): 8 @ $95.68 | EDGAR |
| 2026-01-06 | 4 | KOZARICH JOHN W — Director | Sale (S): 21 @ $186.59 · Sale (S): 91 @ $187.95 · Sale (S): 102 @ $188.96 · Sale (S): 207 @ $190.27 · Sale (S): 46 @ $192.40 | EDGAR |
| 2025-12-18 | 4 | Espinoza Octavio — Chief Financial Officer | Option exercise (M): 1,194 @ $52.84 · Option exercise (M): 69 @ $57.22 · Option exercise (M): 285 @ $63.62 · Option exercise (M): 652 @ $92.65 · Option exercise (M): 181 @ $103.42 · Option exercise (M): 1,194 (derivative) @ $0 · +4 more | EDGAR |
| 2025-12-16 | 4 | Espinoza Octavio — Chief Financial Officer | Sale (S): 1,804 @ $188.31 | EDGAR |
| 2025-12-09 | 4 | Espinoza Octavio — Chief Financial Officer | Tax withholding (F): 1,862 @ $184.87 | EDGAR |
| 2025-12-08 | 4 | Davis Todd C — Chief Executive Officer, Director | Gift (G): 130 @ $0 | EDGAR |
| 2025-12-08 | 4 | Aryeh Jason — Director | Option exercise (M): 2,034 @ $69.51 · Option exercise (M): 2,034 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | KOZARICH JOHN W — Director | Sale (S): 92 @ $193.86 · Sale (S): 179 @ $194.76 · Sale (S): 47 @ $195.80 · Sale (S): 4 @ $196.34 · Sale (S): 92 @ $197.72 · Sale (S): 23 @ $199.22 · +1 more | EDGAR |
| 2025-11-12 | 4 | Gray Nancy Ryan — Director | Option exercise (M): 3,556 @ $66.19 · Sale (S): 3,556 @ $205.45 · Option exercise (M): 3,015 @ $73.57 · Sale (S): 3,015 @ $205.45 · Option exercise (M): 3,556 (derivative) @ $0 · Option exercise (M): 3,015 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | LAMATTINA JOHN L — Director | Option exercise (M): 2,145 @ $66.13 · Sale (S): 2,145 @ $205.45 · Option exercise (M): 2,034 @ $69.51 · Sale (S): 2,034 @ $205.45 · Option exercise (M): 2,145 (derivative) @ $0 · Option exercise (M): 2,034 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | KOZARICH JOHN W — Director | Sale (S): 84 @ $189.00 · Sale (S): 49 @ $190.26 · Sale (S): 207 @ $191.25 · Sale (S): 127 @ $192.38 | EDGAR |
| 2025-10-03 | 4 | KOZARICH JOHN W — Director | Sale (S): 24 @ $177.60 · Sale (S): 196 @ $178.41 · Sale (S): 155 @ $180.01 · Sale (S): 92 @ $181.18 | EDGAR |
| 2025-09-24 | 4 | Zimmermann Martine — Director | Tax withholding (F): 115 @ $170.77 | EDGAR |
| 2025-09-24 | 4 | Aryeh Jason — Director | Sale (S): 4,418 @ $170.41 · Sale (S): 4,628 @ $170.96 · Sale (S): 954 @ $171.92 | EDGAR |
Recent 8-K events — LIGAND PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-04-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LGND returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →